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INTRODUCTION 
Retinoblastoma is the most common intraocular tumor
of childhood and accounts for 11% of all cancers that occur
during the first year of life (1). Because treatments for retino-
blastoma cure over 90% of patients, organ and vision preser-
vation and the minimization of late treatment side-effects
are important secondary treatment goals. Retinoblastoma
had been treated by external beam radiotherapy (EBR), and
for many years this was the accepted treatment standard (2-
7). However, greater knowledge of radiation induced mor-
bidities and of secondary tumor risks after radiation therapy
(8, 9) have encouraged the use of primary chemotherapy plus
conservative focal therapy over the past decade. 
Despite the recent trend toward chemoreduction (10-13),
radiotherapy remains an excellent means of preserving vision
in children (aged >1 yr) with retinoblastoma, because the
tumor is radiosensitive and routinely responds to radiother-
apy. Moreover, technologic advances made in the radiation
oncology enable more precise targeting for tumor, avoiding
healthy tissues, and the risks of secondary nonocular cancer
reduced. Brachytherapy (14-16) has been used for selected
cases in expert hospitals, and stereotactic conformal radiothera-
py (17-19), and proton therapy (20, 21) could also be consid-
ered components in the modern radiotherapy armamentari-
um for retinoblastoma. However, available clinical data for
stereotactic conformal therapy and proton therapy is limited. 
The Korea Cancer Center Hospital (KCCH) has consider-
able experience of treating retinoblastoma in Korea, and thus,
we retrospectively reviewed our experiences of treating reti-
noblastoma patients with EBR, as initial treatment, to deter-
mine its long-term effects on subsequent tumor control, and
its associated complication rates and prognostic factors. In
addition, we reviewed EBR and brachytherapy clinical data
in the hope of providing guidelines regarding indications for
radiation therapy in patients with retinoblastoma. 
MATERIALS AND METHODS
Patients and tumor characteristics 
The medical records of all patients diagnosed as reti-
noblastoma who received EBR as an initial treatment at the
KCCH between July 1987 and June 1998, were reviewed.
A total of 36 eyes in 29 patients with intraocular retino-
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Primary Treatment for Retinoblastoma
The authors reviewed their experiences of external beam radiotherapy (EBR) as
an initial treatment in retinoblastoma patients to determine its long-term effect on
subsequent tumor control and complications. A total of 32 eyes in 25 patients that
underwent EBR for retinoblastoma were reviewed retrospectively. The patients con-
sisted of 21 boys and 4 girls of median age at treatment of 7.1 months. Radiation
doses ranged from 35 to 59.4 Gy. The 10-yr ocular and patient survivals were 75.4%
and 92.3%, respectively. Nine of the 32 eyes progressed; 7 of these were enucle-
ated and 2 were salvaged by focal treatment. According to the Reese-Ellsworth clas-
sification, 4 of 5 eyes of Group II, 13 of 16 Group III eyes, 2 of 4 Group IV eyes, and
5 of 7 Group V eyes were retained, and of the 32 eyes, 13 had visual acuity better
than 20/200. Eleven patients experienced a radiation-induced complication. No patient
developed a second malignancy during follow-up. Despite the limited number of
patients enrolled, EBR may provide a mean of preserving eyeball and vision for
some advanced lesions.
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blastoma underwent EBR as an initial treatment. Of these,
4 patients were excluded due to a short follow-up duration
(<3 yr). Patient details and data concerning tumor features,
treatment parameters, and complications were collected by
chart review. 
The characteristics of patients and tumors are described in
Table 1. Briefly, the study subjects were 21 boys and 4 girls
of median age at treatment commencement of 7.1 months
(range 7 weeks to 65 months). Twenty-one presented with
bilateral involvement and 4 with unilateral disease. The most
frequent presenting finding was leukocoria in 16 patients
(64%) followed by strabismus in 6 (24%). For the 21 patients
with bilateral involvement, 28 eyes received external beam
radiation, and 14 eyes were enucleated due to advanced dis-
ease without visual potential before EBR. Of the 32 eyes treat-
ed, 0 were of Reese-Ellsworth (RE) Group I, 5 were Group
II, 16 were Group III, 4 were Group IV, and 7 were Group
V (5 in RE Group Va and 2 in RE Group Vb). All of two
eyes in Group Vb had a localized vitreous seeding pattern. 
Treatment and follow-up
Treatment simulation was done for with patients under
sedation while wearing a thermoplast head mask immobiliza-
tion device. All patients were treated in the supine position
using a linear accelerator at a photon energy of 6 MV with
compensating bolus as needed. Twenty patients (27 eyes) were
treated using opposed lateral fields alone (mainly patients with
bilateral disease), while five patients (5 eyes) were treated using
anterior and lateral wedged pair fields with no attempt to
shield the lens. The most frequently used field size (exclud-
ing half beam blocking) was 4×4 cm, but field sizes ranged
from 3×3.5 cm to 6×4 cm. Treatment doses ranged from
35 to 59.4 Gy (median 41.6 Gy) in fractions of 1.6 to 2.0 Gy. 
Chemotherapy was usually administered for high stage con-
tralateral tumors that had been enucleated to control micro-
Pt, patient; RE, reese-ellsworth classification; OS, oculus survival; Od, oculus dexter; Os, ocular sinister; Bil, bilateral; LP, light perception; LR, local
recurrence; Un, unilateral; RD, retinal detachment; VH, vitreous hemorrhage; HM, hand motion.
Irradiated
eye
RE
Dose
(Gy)
Clinical course Visual acuity OS (mon) Complications Pt
1 Od (Bil) 2a 37.4 LP (+) 80
Os (Bil) 3a 50.0 20/250 80
2 Od (Bil) 3a 38.0 Phthisis→enucleation Enucleation 74 Cataract, phthisis
Os (Bil) 4a 38.0 LR Enucleation 35
3 Od (Bil) 2a 43.0 LP (+) 116
Os (Bil) 3a 43.0 20/20 116
4 Os (Bil) 2a 46.0 20/30 140 Cataract
Od (Bil) 3a 44.0 LR Enucleation  16
5 Od (Bil) 3a 48.0 20/1000 150
Os (Bil) 3a 49.0 20/15 150
6 Od (Bil) 5a 50.0 LR Enucleation 8
Os (Bil) 5b 50.0 20/25 104
7 Od (Bil) 5a 59.4 20/1000 153
Os (Bil) 5a 50.0 LR Enucleation 10
8 Os (Un) 2b 35.0 LR Enucleation 13 RD, VH, facial asymmetry
9 Os (Bil) 4a 38.0 LR Enucleation 34 Cataract
10 Os (Bil) 3a 38.0 20/25 127 Cataract
11 Os (Un) 3a 38.0 20/500 117
12 Os (Bil) 3a 38.0 20/25 131 RD
13 Os (Bil) 3a 41.0 LR→laser 20/60 64
14 Os (Bil) 3a 41.0 20/25 96
15 Od (Bil) 4a 41.6 LR→cryotherapy 20/1000 148 Cataract, RD, VH
16 Os (Bil) 2a 41.6 20/100 105
17 Od (Bil) 3a 41.6 20/150 136 Cataract
18 Os (Bil) 5b 45.0 20/25 71
19 Od (Bil) 4a 46.0 20/20 78
20 Od (Un) 3a 46.0 LR Enucleation 37
21 Od (Bil) 3a 46.8 HM (+) 85 Cataract
22 Od (Bil) 5a 48.0 20/500 150 Cataract
23 Os (Bil) 3a 48.0 20/100 55
24 Os (Bil) 3a 48.0 20/50 132
25 Os (Un) 5a 56.0 LP (+) 78 Cataract, RD, 
microophthalmia
Table 1. Demographic data for retinoblastoma patients548 S.Y. Choi, M.-S. Kim, S.Y. Yoo, et al.
scopic tumors. Twenty-two patients received cyclophospha-
mide plus vincristine with or without doxorubicin at various
doses and cycle numbers. 
Additional cryotherapy or laser therapy was administered
after EBR when tumor progression was detected. Enucleation
was performed in cases with definite tumor progression after
additional treatment or due to a severe complication.
Evaluations and statistics 
Evaluations were performed at each follow-up to determine
tumor sizes and visual acuities, and to detect new lesions and
complications, such as, retinopathy, cataract, neovascular glau-
coma, and midfacial hypoplasia. In addition, we analyzed prog-
nostic factors, such as, gender, age, and the RE classification
according to ocular survival using the log-rank test. In addi-
tion, the relationship between RE classification and visual
acuity was analyzed using the t-test. The Kaplan-Meier me-
thod was used to estimate overall and ocular survivals. Over-
all survival was calculated from EBR commencement to final
follow-up or death, whereas ocular survival was calculated
from EBR commencement to time of enucleation or final fol-
low-up with an intact eye. 
RESULTS 
Median follow up was 150 months (range 55-249 months),
and the 10-yr ocular and overall survival rates were 75.4%
and 92.3%, respectively (Fig. 1). Two patients died after in-
volvement of the central nervous system. 
Nine of the 32 eyes developed new lesions or reactivation
of previous lesions. Of these, 7 eyes were enucleated and 2
were salvaged by cryotherapy and laser treatment (Table 1).
One additional enucleation was performed due to phthisis
bulbi (patient No. 2 in Table 1). Therefore, ocular preserva-
tion was achieved in 24 of the 32 (75.4%) eyes. According
to RE classification, 4 of 5 eyes were retained in Group II,
13 of 16 in Group III, 2 of 4 in Group IV, and 5 of 7 in Group
V. Vision was preserved in 24 (75%) out of 32 treated eyes.
Of the preserved 24 eyes, 9 (37.5%) had a visual acuity bet-
ter than 20/40; 5 (20.8%) had an acuity worse than 20/40
but better than 20/200, and 10 (41.7%) had vision worse than
20/200. All the patients with visual acuity less than 20/200
presented with the involvement of the posterior pole, and
showed macular degeneration following treatment.
Records showed that 11 patients experienced a radiation-
induced complication; 6 had cataracts alone, 1 had retinal
detachment alone and 4 had one more complications (Table
1). Nine cataracts were recorded and removed when neces-
sary, and vision restoration or improvement was achieved in
all cases. The median time to cataract development was 5 yr
and 9 months (range 13 to 125 months). Serous retinal detach-
ment was detected in 3 eyes; 2 were transient and reattached
after 3 months and 6 months respectively. One patient devel-
oped vitreous hemorrhage and underwent enucleation. Midfa-
cial hypoplasia occurred to some degree in all patients. Typi-
cally, deforming hypoplasia was recorded in 2 patients. Fig.
2 shows typical hypoplasia in a treated eye by CT and pho-
tography. No patient developed a second malignancy during
follow-up.
An age of less than 13 months was found to be a signifi-
cantly favorable factor of ocular survival by univariate analy-
sis, but this was not confirmed by multivariate analysis. No
Fig. 1. Overall and ocular survival.
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Fig. 2. Midfacial hypoplasia and microophthalmia. (A) Midfacial
hypoplasia is noted on the right. (B) CT scan shows smaller eye-
ball and orbit on the left.
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other prognostic factor was identified during this study (Table
2), and in particular, no significant relationship was found
between RE classification and visual acuity. 
DISCUSSION
EBR has a valuable role in the treatment of retinoblastoma,
but radiation-induced secondary tumors jeopardize the role
played by EBR in retinoblastoma. Large-scale cohort studies
performed to quantify cancer risks in retinoblastoma treated
by radiotherapy (9) have found that radiotherapy contribut-
ed significantly to the risks of developing brain, nasal cavi-
ty, and eye and orbit cancers. Notably, the risk of cancer of
the nasal cavity increased by 1,364-fold in hereditary retino-
blastoma treated by EBR. External beam radiation is usual-
ly favored for the treatment of bilateral retinoblastoma, which
is almost always hereditary, and thus, all possible efforts should
be made to reduce the risk of secondary malignancies after
radiotherapy. 
Various EBR techniques have been developed to reduce radi-
ation dose to the lens. A review of EBR technology revealed
that the lateral field is usually used because it requires lower
lens doses (2-7). In most cases, radiation-induced cataract is
not an obstacle to the vision preservation. However, reduc-
tions in doses administered to the orbital cavity, optic nerve,
or cranial bone appear to be more important. Recently, more
meticulous techniques, such as, intensity modulated radia-
tion therapy (IMRT) and stereotactic hypofractionated radi-
ation therapy, have been introduced, which administer lower
doses of radiation to critical organs. Reisner et al. (7) compared
several EBR techniques, that is, electron beam, the lateral 2
field and anterior-lateral 2 field techniques, and IMRT, and
found that IMRT had an advantage over the other techniques,
because it allowed greater dose reductions to the orbit and
lacrimal gland, while maintaining therapeutic doses to the
ora serrata retinae and vitreous. Recently, Sahgal et al. (18)
reported that stereotactic fractionated radiation therapy for
localized tumor masses can achieve markedly lower doses to
surrounding critical normal tissues than conventional radia-
tion therapy. Furthermore, proton therapy (20, 21) is also
likely to reduce cranial bone radiation dose due to the radia-
tion quality of the Bragg peak. However, few clinical trials
have been performed and clinical data is scarce.
Brachytherapy (14-16) was introduced in the 1920’s to
treat ocular tumors and reduce the exposure to normal tis-
sue around tumors, and has been further developed in terms
of new radioisotopes, implant designs, and techniques of place-
ment. Table 3 details the ocular survival and cataract inci-
dence rates of conventional radiation therapy techniques and
LC, local control; NA, not assessed; MV, megavoltage; MeV, megavoltage electron.
Series Year
No. of 
eyes
Method
Dose (Gy)/
Fraction No. or dose
Ocular 
survival 
rate (%)
Incidences 
of cataract
(%)
Method of 
radiation
EBR Schipper (3) 1983 54 Oblique 6 MV photon enhanced  45/15 fraction 81 33
dynamic wedge
Hernandez (24) 1996 34 Ant & lateral 4 MeV photon field,  34.5-49.5/1.5-2.0 Gy 73 41
no lens shielding
Blach (25) 1996 113 lat collimated 6 MV photon field 42-46/21-23 fraction 84 (LC) 22
67 Ant lens-sparing electron beam 38-50/15-20 fraction 38 (LC)
Phillips (2) 2003 47 single and two field technique 30-50/(about 2 Gy) 72 23
Present series 32 Lat or ant & lateral 6 MeV photon field  35-55/(1.6-2.0 Gy) 74 28
Brachy- Shields (14) 2001 208 I-125(178), 106-Ru(7) Co-60(17), 40 to tumor apex 79 31
therapy I-192(6)
Merchant (22) 2004 25 I-125 44 (35-47.6) to tumor apex 60 (crude) NA
Shields (16) 2006 84 I-125 40 to tumor apex +2 mm 95 43
Schueler (15) 2006 175 106-Ru 50 or 70 to tumor apex 87 17
Abouzeid (23) 2008 41 106-Ru 50 to tumor apex 76 (crude) 10
Table 3. Review of retinoblastoma treated by EBR or plaque brachytherapy
Prognostic factors
No. of
cases
Ocular 
survival (%)
P value
Gender
Male 25 75.3 0.7
Female 7 71.4
Age (mon)
<13 17 94.1 0.008
≥13 15 52.5
RE
2-3 21 80.0 0.2
4-5 11 63.6
RT dose (Gy)
<41 8 50.0 0.08
≥41 24 83.3
Table 2. Prognostic factors by univariate analysis
RE, Reese-Ellsworth classification; RT, radiotherapy.550 S.Y. Choi, M.-S. Kim, S.Y. Yoo, et al.
brachytherapy; it is worth noting that the radiation doses,
fraction numbers, and beam delivery techniques used at dif-
ferent institutes over the last 20 yr has varied considerably.
The literature review revealed that ocular survival ranged
from 38% to 84% (median 73%) for EBR, but from 60%
to 95% (median 79%) for brachytherapy. Furthermore, radi-
ation-induced cataract was found to be the most common
complication of radiation therapy; the incidence of cataract
ranged from 22% to 41% (median 28%) for EBR and from
10% to 43% (median 17%) for brachytherapy. However, it
should be noted that because retinoblastoma is rarely encoun-
tered in infants, skilled treatment is required to obtain good
outcomes after EBR and brachytherapy. 
In the present study, we analyzed patient and ocular sur-
vivals, and long-term treatment toxicities. Our results, in
terms of ocular survival and the incidence of cataract, com-
pare well with those of other EBR series (22-25). Long-term
follow-up findings revealed that late radiation effects were
milder than expected, and that favorable visual outcome had
been maintained. Furthermore, ocular survival analysis by
RE classification, despite the limitations imposed by small
patient numbers, showed that involved eyes with an RE clas-
sification of 4 or 5 achieved 64% ocular survival, which indi-
cates that radiation therapy should be considered before enu-
cleation as primary or secondly treatment for even advanced
retinoblastoma.
In conclusion, our long-term results show that EBR has
an important role to play in the avoidance of enucleation in
retinoblastoma with small lesions or advanced lesions with
vitreous seeding. Furthermore, non-conventional radiation
therapies as brachytherapy, stereotactic radiotherapy, IMRT,
and proton therapy, are likely to reduce complication rates.
Additional research is required to establish new indications
for the various radiation therapy techniques available for the
treatment of retinoblastoma. 
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